US20030010718A1 - Hemodilution cap and methods of use in blood-processing procedures - Google Patents
Hemodilution cap and methods of use in blood-processing procedures Download PDFInfo
- Publication number
- US20030010718A1 US20030010718A1 US09/904,709 US90470901A US2003010718A1 US 20030010718 A1 US20030010718 A1 US 20030010718A1 US 90470901 A US90470901 A US 90470901A US 2003010718 A1 US2003010718 A1 US 2003010718A1
- Authority
- US
- United States
- Prior art keywords
- blood
- outlet
- inlet
- filter
- housing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 53
- 238000012545 processing Methods 0.000 title claims abstract description 19
- 206010059484 Haemodilution Diseases 0.000 title claims abstract description 18
- 239000008280 blood Substances 0.000 claims abstract description 116
- 210000004369 blood Anatomy 0.000 claims abstract description 116
- 239000012530 fluid Substances 0.000 claims abstract description 63
- 238000010790 dilution Methods 0.000 claims abstract description 32
- 239000012895 dilution Substances 0.000 claims abstract description 32
- 239000002699 waste material Substances 0.000 claims abstract description 20
- 239000000835 fiber Substances 0.000 claims description 19
- 238000001802 infusion Methods 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 7
- 239000008156 Ringer's lactate solution Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 206010018873 Haemoconcentration Diseases 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000002615 hemofiltration Methods 0.000 abstract description 19
- 206010053567 Coagulopathies Diseases 0.000 abstract description 6
- 230000035602 clotting Effects 0.000 abstract description 6
- 238000001631 haemodialysis Methods 0.000 abstract description 6
- 230000000322 hemodialysis Effects 0.000 abstract description 6
- 238000000502 dialysis Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 8
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 4
- 238000004382 potting Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000010408 sweeping Methods 0.000 description 2
- 108010029144 Factor IIa Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
- B01D63/034—Lumen open in more than two directions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3431—Substitution fluid path upstream of the filter
- A61M1/3434—Substitution fluid path upstream of the filter with pre-dilution and post-dilution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3437—Substitution fluid path downstream of the filter, e.g. post-dilution with filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/20—Accessories; Auxiliary operations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/24—Dialysis ; Membrane extraction
- B01D61/30—Accessories; Auxiliary operation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/21—Specific headers, end caps
Definitions
- the present invention relates generally to devices and methods useful in preventing coagulation in filtered blood during hemofiltration. More specifically, the devices and methods provide a cap having a port, the cap adapted for attachment to a blood filter housing to provide hemodilution of blood as it enters and/or exits the filter.
- the intrinsic system There are two separate coagulation pathways that activate factor X—the intrinsic system and the extrinsic system. Activation of the extrinsic system requires tissue thromboplastin (factor III), which is released from damaged tissue into the circulating blood to activate clotting.
- the intrinsic system has all the factors necessary for coagulation contained in the circulating blood. The intrinsic system is, for example, partially responsible for clotting of blood in a test tube. Aggregation of platelets caused by stagnation of blood also facilitates blood coagulation.
- the present invention provides devices and methods that prevent clotting of blood during blood-processing procedures, such as hemofiltration, hemodialysis, and hemodiafiltration. More particularly, blood is diluted by replacement fluid, such as saline, Ringer's lactate, or other physiological solutions, as it enters and/or exits the filter.
- the device also known as a filter, is comprised of a bundle of hollow fiber membrane made of resins such as polysulfone that is fixed in a cylindrical housing with a potting material. The interior of the fibers is the blood flow path. The exterior of the fibers is the dialysate and/or waste space.
- the potting material is typically a polyurethane material.
- the cylindrical housing may have one or two access ports.
- One port is for the hemofiltration filter, and two ports allow dialysate to flow through the housing contacting the exterior surface of the membrane for hemodialysis or hemodiafiltration.
- the open fibers at the end of the cylindrical housing are covered at both ends with a cap.
- One cap is the blood entry cap, the other is the blood exit cap.
- the housing includes end plates at one or both ends, the end plates integral with the housing.
- the exit cap is attached to the housing, in some cases removably attached, and generally at a position opposite the inlet cap.
- the exit cap has an outlet for blood and a port adjacent the outlet for receiving replacement fluid.
- the blood outlet, the replacement fluid port, the blood inlet, and/or the waste outlet of the filter assembly communicate with bond sockets adapted to receive flexible tubing.
- the filter has an outlet or exit cap for blood at one end and an inlet or inlet cap at the other end, the cap having an inlet for blood and a port adjacent to the inlet for receiving dilution fluid, such as saline, Ringer's lactate, or other physiological solutions.
- the housing also includes access ports for waste and ultrafiltrate.
- the housing includes first and second caps at opposite ends and an outlet for waste and ultrafiltrate.
- the first cap has an inlet for blood and a port adjacent to the inlet for receiving dilution fluid.
- the second cap has an outlet for blood and a port adjacent to the outlet for receiving dilution fluid.
- blood is passed through the blood inlet of the entry cap, through the filter membrane fibers, and through the blood outlet of the exit cap.
- Replacement fluid or dilution fluid such as saline, Ringer's lactate, or other physiological solutions, is infused into the port adjacent the blood outlet to produce hemodilution at the blood outlet.
- the fluid is infused into the port adjacent the blood inlet of the entry cap to produce hemodilution at the inlet.
- fluid is infused into the port adjacent the blood inlet of the entry cap and into the port adjacent the blood outlet of the exit cap to produce hemodilution as blood enters and exits the filter housing.
- the replacement fluid swirls in a circular pattern in a headspace that is defined by the gap between the filter and the cap. Swirling of the replacement fluid facilitates mixing of the fluid and the blood, thereby preventing hemoconcentration and stasis of blood, and sweeping any particles of thrombus away from the filter.
- the advantages associated with the hemodilution cap described herein include (1) preventing coagulation during blood processing procedures, (2) manufacturing efficiency, i.e., reducing plastic used in disposable components, (3) eliminating up to two bonds and up to two components, (4) less expense in materials costs and manufacturing costs, (5) more robust system, not subject to tolerances like bonding two rigid parts, and (6) integration of parts saves labor, materials, and precious resources.
- FIG. 1A depicts a filter within a housing for hemofiltration.
- FIG. 1B depicts a filter within a housing having a replacement fluid port adjacent the blood outlet port for hemofiltration.
- FIG. 1C depicts a filter within a housing having a replacement fluid port adjacent the blood inlet port for hemofiltration.
- FIG. 1D depicts a filter within a housing having replacement fluid ports adjacent both the blood inlet port and the blood outlet port for hemofiltration.
- FIG. 1E depicts a filter within a housing for hemodiafiltration having dialysate inlet and outlet ports.
- FIG. 1F depicts a filter within a housing for hemodiafiltration having a replacement fluid port adjacent the blood outlet port.
- FIG. 2 depicts a filter-housing cap having a replacement fluid port adjacent the blood outlet port for hemofiltration.
- FIG. 3A depicts a cross-sectional view of a filter housing cap having a replacement fluid port adjacent the blood outlet port for hemofiltration.
- FIG. 3B depicts another cross-sectional view of a filter housing cap having a replacement fluid port adjacent the blood outlet port for hemofiltration.
- FIG. 3C depicts another cross-sectional view of a filter housing cap having a replacement fluid port adjacent the blood outlet port and a headspace for hemofiltration.
- FIG. 4A depicts a fluid bond socket communicating with the blood outlet.
- FIG. 4B depicts a fluid bond socket communicating with the replacement fluid port.
- FIG. 5 depicts a filter-housing cap removably mounted on a filter housing for hemofiltration.
- FIG. 6 depicts a filter-housing cap for hemofiltration, the cap being made of flexible PVC and having ribs for stability.
- the hemofiltration device includes cylindrical housing 10 which contains filter fibers 20 that remove waste from blood passing through the fibers. It will be understood that any other suitable shape can be used for the housing. Housing 10 is equipped with entry cap 13 having blood inlet 11 . Waste and ultrafiltrate that are removed from the blood exits the housing through waste outlet 12 . Exit cap 30 is mounted on housing 10 opposite blood entry cap 13 . Headspace 31 is formed in the gap between filter fibers 20 and cap 30 and between filters 20 and cap 13 . Headspace 31 communicates with blood outlet 32 . Each of the inlet 11 waste outlet 12 and blood outlet 32 are adapted for attachment to flexible tubing sections that connect with a blood processing system.
- cap 30 further includes replacement fluid inlet port 33 that communicates with headspace 31 .
- Replacement fluid is infused through port 33 to effect hemodilution of blood exiting filter 20 .
- the system thereby reconstitutes blood as close as possible to the exit from the filter fibers. In this way hemodilution is accomplished with one part (cap 30 ) and two bonds (one between tubing and port 32 , and another between tubing and port 33 ).
- housing 10 includes cap 13 having blood inlet 11 and dilution fluid inlet port 15 that communicates with headspace 31 . Blood is diluted as it enters housing 10 , thereby helping to prevent coagulation.
- housing 10 includes cap 13 having blood inlet and dilution fluid inlet port 15 that communicates with headspace 31 .
- the housing also includes cap 30 having blood outlet 32 and fluid inlet port 33 that communicates with headspace 31 .
- Dilution fluid is infused through port 33 and port 15 to effect hemodilution of blood entering and exiting filter 20 .
- FIG. 1E shows a housing 10 designed for hemodiafiltration.
- Housing 10 includes dialysate inlet 16 and dialysate outlet 12 to establish countercurrent dialysate flow.
- Filter fiber membrane 20 is mounted within potting material 21 at both ends, where the potting material typically is a polyurethane material.
- cap 30 further includes replacement fluid inlet port 33 that communicates with headspace 31 .
- Replacement fluid is infused through port 33 to effect hemodilution of blood exiting filter 20 as described for other embodiments above. It will be understood that for hemodiafiltration, a hemodilution cap may be included alternatively on the inlet to effect pre-dilution of blood, and/or on both the inlet and outlet.
- FIG. 2 shows a top view of cap 30 having blood outlet 32 and replacement fluid infusion port 33 .
- replacement fluid such as saline, Ringer's lactate, sterile filtered dialysate, or other physiological solutions
- Inlet blood flow rate will typically be 50-1000 mL/min, preferably 350-600 mL/min.
- Infusion of dilution fluid at the exit cap will generally be 1-50% of inlet blood flow, preferably 20-30% in order to establish swirling.
- Infusion port 33 includes bond socket 34
- outlet 32 includes bond socket 35 .
- Each bond socket is adapted to receive flexible tubing.
- the tubing is generally constructed of PVC and the bond socket is constructed of any one of a number of thermoplastic resins including PVC, polycarbonate, ABS, etc., PVC being preferable as it is solvent bonded to the housing, the tubing may be fused to the bond socket by brief immersion in cyclohexanone or other suitable organic solvent before inserting the tubing in the bond socket.
- Soft PVC is flexible, allowing the cap to have an interference fit when solvent bonded. This makes it less susceptible to tolerance problems.
- FIG. 3A depicts a side view of an embodiment of cap 30 with blood outlet 32 and bond socket 35 .
- FIG. 3B depicts a side view of another embodiment of cap 30 having blood outlet 32 and bond socket 35 .
- FIG. 3C depicts a side view of still another embodiment of cap 30 having blood outlet 32 and bond socket 35 .
- Filter housing 10 is slideably received within the opening in cap 30 when fully inserted, housing 10 rests against annular ridge 36 .
- Headspace 31 is defined by the gap between filter 20 and cap 30 .
- FIG. 4A shows the details of bond socket 35 communicating with the blood outlet designed for interference fit with appropriately sized tubing.
- Passage 41 has a dimension of approximately 0.185 inches in diameter.
- Surface 43 is approximately 0.248 inches in diameter.
- Annular member 42 has a height of approximately 0.35 inches.
- Surface 45 is approximately 0.252 inches in diameter.
- blood outlet 32 communicates with a quarter inch bond socket.
- Replacement fluid infusion port 33 communicates with bond socket 34 shown in details in FIG. 4B.
- Passage 41 has a dimension of approximately 0.098 inches in diameter.
- Surface 43 is approximately 0.142 inches in diameter.
- Annular member 42 has a height of approximately 0.31 inches.
- Surface 45 is approximately 0.147 inches in diameter.
- FIG. 5 depicts housing 10 inserted within cap 30 .
- Headspace 31 communicates with outlet 32 , which in turn communicates with bond socket 35 .
- Headspace 31 ranges from approximately 1.5 mm at the outer edge to approximately 3 mm in the center of the dome-like region.
- the pressure in headspace 31 can reach 40 PSI (2000 mmHg), resulting in 25 lbs force pushing the cap off.
- the cap 30 may therefore need to be bonded, threaded, or snapped on, or attached by other suitable means, to withstand pressure. Solvent bonding and use of a threaded cap are two suitable means to accomplish attachment. It will again be understood that these device dimension are merely illustrative as stated above.
- FIG. 6 depicts a top view of another embodiment of cap 30 having ribs 37 .
Abstract
Devices and methods that prevent clotting of blood during blood-processing procedures such as hemofiltration, hemodialysis, hemodiafiltration, and peritoneal dialysis are described. The device comprises a cap and a housing that is shaped to receive a blood filter. The housing has an inlet for blood and may have an outlet for waste and ultrafiltrate. The cap is attached to the housing. The cap has an outlet for blood and a port adjacent the outlet for receiving dilution fluid. Methods of use during blood-processing procedures to provide immediate hemodilution to blood exiting a filter are also described.
Description
- The present invention relates generally to devices and methods useful in preventing coagulation in filtered blood during hemofiltration. More specifically, the devices and methods provide a cap having a port, the cap adapted for attachment to a blood filter housing to provide hemodilution of blood as it enters and/or exits the filter.
- Undesired coagulation of blood often complicates blood-processing procedures such as hemofiltration, hemodialysis, and hemodiafiltration, particularly where a filter is used. Blood generally coagulates by transforming soluble fibrinogen into insoluble fibrin by activation of numerous circulating proteins that interact in a cascading series of limited proteolytic reactions. At each step of reaction, a clotting factor undergoes limited proteolysis and becomes an active protease that in turn activates the next clotting factor until finally a solid fibrin clot is formed. Fibrinogen (factor I) is activated by thrombin (factor IIa), which is converted from prothrombin by activated factor X. There are two separate coagulation pathways that activate factor X—the intrinsic system and the extrinsic system. Activation of the extrinsic system requires tissue thromboplastin (factor III), which is released from damaged tissue into the circulating blood to activate clotting. The intrinsic system, on the other hand, has all the factors necessary for coagulation contained in the circulating blood. The intrinsic system is, for example, partially responsible for clotting of blood in a test tube. Aggregation of platelets caused by stagnation of blood also facilitates blood coagulation.
- During hemofiltration, for example, blood is removed from the patient, filtered through a filtering column to remove waste products, and returned to the patient's circulation. However, during removal of waste products, fluid is also removed, causing concentration of blood leaving the outflow tubing. As a result of hemoconcentration, hematocrit rises, and the intrinsic coagulation pathway and platelets are activated causing clotting of blood around the outlet of the filtering column, thereby compromising the hemofiltrating process.
- What is needed are devices and methods that can be used with a filtering column during blood-processing procedures, such as hemofiltration, hemodialysis, hemodiafiltration, and peritoneal dialysis, to prevent clotting. Existing devices are inadequate for this purpose.
- The present invention provides devices and methods that prevent clotting of blood during blood-processing procedures, such as hemofiltration, hemodialysis, and hemodiafiltration. More particularly, blood is diluted by replacement fluid, such as saline, Ringer's lactate, or other physiological solutions, as it enters and/or exits the filter. In a first embodiment, the device, also known as a filter, is comprised of a bundle of hollow fiber membrane made of resins such as polysulfone that is fixed in a cylindrical housing with a potting material. The interior of the fibers is the blood flow path. The exterior of the fibers is the dialysate and/or waste space. The potting material is typically a polyurethane material. The cylindrical housing may have one or two access ports. One port is for the hemofiltration filter, and two ports allow dialysate to flow through the housing contacting the exterior surface of the membrane for hemodialysis or hemodiafiltration. In one embodiment, the open fibers at the end of the cylindrical housing are covered at both ends with a cap. One cap is the blood entry cap, the other is the blood exit cap. In other embodiments, the housing includes end plates at one or both ends, the end plates integral with the housing.
- The exit cap is attached to the housing, in some cases removably attached, and generally at a position opposite the inlet cap. The exit cap has an outlet for blood and a port adjacent the outlet for receiving replacement fluid. In certain embodiments, the blood outlet, the replacement fluid port, the blood inlet, and/or the waste outlet of the filter assembly communicate with bond sockets adapted to receive flexible tubing.
- In another embodiment, the filter has an outlet or exit cap for blood at one end and an inlet or inlet cap at the other end, the cap having an inlet for blood and a port adjacent to the inlet for receiving dilution fluid, such as saline, Ringer's lactate, or other physiological solutions. The housing also includes access ports for waste and ultrafiltrate.
- In still another embodiment, the housing includes first and second caps at opposite ends and an outlet for waste and ultrafiltrate. The first cap has an inlet for blood and a port adjacent to the inlet for receiving dilution fluid. The second cap has an outlet for blood and a port adjacent to the outlet for receiving dilution fluid.
- In use, blood is passed through the blood inlet of the entry cap, through the filter membrane fibers, and through the blood outlet of the exit cap. Replacement fluid or dilution fluid, such as saline, Ringer's lactate, or other physiological solutions, is infused into the port adjacent the blood outlet to produce hemodilution at the blood outlet. Alternatively, the fluid is infused into the port adjacent the blood inlet of the entry cap to produce hemodilution at the inlet. In still another alternative method, fluid is infused into the port adjacent the blood inlet of the entry cap and into the port adjacent the blood outlet of the exit cap to produce hemodilution as blood enters and exits the filter housing. In certain constructions the replacement fluid swirls in a circular pattern in a headspace that is defined by the gap between the filter and the cap. Swirling of the replacement fluid facilitates mixing of the fluid and the blood, thereby preventing hemoconcentration and stasis of blood, and sweeping any particles of thrombus away from the filter.
- The advantages associated with the hemodilution cap described herein include (1) preventing coagulation during blood processing procedures, (2) manufacturing efficiency, i.e., reducing plastic used in disposable components, (3) eliminating up to two bonds and up to two components, (4) less expense in materials costs and manufacturing costs, (5) more robust system, not subject to tolerances like bonding two rigid parts, and (6) integration of parts saves labor, materials, and precious resources.
- FIG. 1A depicts a filter within a housing for hemofiltration.
- FIG. 1B depicts a filter within a housing having a replacement fluid port adjacent the blood outlet port for hemofiltration.
- FIG. 1C depicts a filter within a housing having a replacement fluid port adjacent the blood inlet port for hemofiltration.
- FIG. 1D depicts a filter within a housing having replacement fluid ports adjacent both the blood inlet port and the blood outlet port for hemofiltration.
- FIG. 1E depicts a filter within a housing for hemodiafiltration having dialysate inlet and outlet ports.
- FIG. 1F depicts a filter within a housing for hemodiafiltration having a replacement fluid port adjacent the blood outlet port.
- FIG. 2 depicts a filter-housing cap having a replacement fluid port adjacent the blood outlet port for hemofiltration.
- FIG. 3A depicts a cross-sectional view of a filter housing cap having a replacement fluid port adjacent the blood outlet port for hemofiltration.
- FIG. 3B depicts another cross-sectional view of a filter housing cap having a replacement fluid port adjacent the blood outlet port for hemofiltration.
- FIG. 3C depicts another cross-sectional view of a filter housing cap having a replacement fluid port adjacent the blood outlet port and a headspace for hemofiltration.
- FIG. 4A depicts a fluid bond socket communicating with the blood outlet.
- FIG. 4B depicts a fluid bond socket communicating with the replacement fluid port.
- FIG. 5 depicts a filter-housing cap removably mounted on a filter housing for hemofiltration.
- FIG. 6 depicts a filter-housing cap for hemofiltration, the cap being made of flexible PVC and having ribs for stability.
- During blood-processing procedures, such as hemofiltration, hemodialysis, and hemodiafiltration, blood has a tendency to clot as it passes through processing equipment, particularly where it exits the outlet of a filter, due to hemoconcentration. In FIG. 1A, the hemofiltration device includes
cylindrical housing 10 which containsfilter fibers 20 that remove waste from blood passing through the fibers. It will be understood that any other suitable shape can be used for the housing.Housing 10 is equipped withentry cap 13 having blood inlet 11. Waste and ultrafiltrate that are removed from the blood exits the housing throughwaste outlet 12.Exit cap 30 is mounted onhousing 10 oppositeblood entry cap 13.Headspace 31 is formed in the gap betweenfilter fibers 20 andcap 30 and betweenfilters 20 andcap 13.Headspace 31 communicates withblood outlet 32. Each of the inlet 11waste outlet 12 andblood outlet 32 are adapted for attachment to flexible tubing sections that connect with a blood processing system. - In FIG. 1B,
cap 30 further includes replacementfluid inlet port 33 that communicates withheadspace 31. Replacement fluid is infused throughport 33 to effect hemodilution ofblood exiting filter 20. The system thereby reconstitutes blood as close as possible to the exit from the filter fibers. In this way hemodilution is accomplished with one part (cap 30) and two bonds (one between tubing andport 32, and another between tubing and port 33). - In FIG. 1C,
housing 10 includescap 13 having blood inlet 11 and dilutionfluid inlet port 15 that communicates withheadspace 31. Blood is diluted as it entershousing 10, thereby helping to prevent coagulation. - In FIG. 1D,
housing 10 includescap 13 having blood inlet and dilutionfluid inlet port 15 that communicates withheadspace 31. The housing also includescap 30 havingblood outlet 32 andfluid inlet port 33 that communicates withheadspace 31. Dilution fluid is infused throughport 33 andport 15 to effect hemodilution of blood entering and exitingfilter 20. - FIG. 1E shows a
housing 10 designed for hemodiafiltration.Housing 10 includesdialysate inlet 16 anddialysate outlet 12 to establish countercurrent dialysate flow.Filter fiber membrane 20 is mounted withinpotting material 21 at both ends, where the potting material typically is a polyurethane material. In FIG. 1F, cap 30 further includes replacementfluid inlet port 33 that communicates withheadspace 31. Replacement fluid is infused throughport 33 to effect hemodilution ofblood exiting filter 20 as described for other embodiments above. It will be understood that for hemodiafiltration, a hemodilution cap may be included alternatively on the inlet to effect pre-dilution of blood, and/or on both the inlet and outlet. - FIG. 2 shows a top view of
cap 30 havingblood outlet 32 and replacementfluid infusion port 33. In use, replacement fluid, such as saline, Ringer's lactate, sterile filtered dialysate, or other physiological solutions, enters throughport 33 and establishes a swirling current withinheadspace 31. This current has the beneficial effect of sweeping thrombus particles that may have accumulated in the headspace and flushing the particle throughoutlet 32. Inlet blood flow rate will typically be 50-1000 mL/min, preferably 350-600 mL/min. Infusion of dilution fluid at the exit cap will generally be 1-50% of inlet blood flow, preferably 20-30% in order to establish swirling. The foregoing ranges are set forth solely for the purpose of illustrating typical operating parameters. The actual parameters for operation of a device constructed according to the principles of the present invention may obviously vary outside of the listed ranges without departing from those basic principles. -
Infusion port 33 includesbond socket 34, andoutlet 32 includesbond socket 35. Each bond socket is adapted to receive flexible tubing. Where the tubing is generally constructed of PVC and the bond socket is constructed of any one of a number of thermoplastic resins including PVC, polycarbonate, ABS, etc., PVC being preferable as it is solvent bonded to the housing, the tubing may be fused to the bond socket by brief immersion in cyclohexanone or other suitable organic solvent before inserting the tubing in the bond socket. Soft PVC is flexible, allowing the cap to have an interference fit when solvent bonded. This makes it less susceptible to tolerance problems. - FIG. 3A depicts a side view of an embodiment of
cap 30 withblood outlet 32 andbond socket 35. FIG. 3B depicts a side view of another embodiment ofcap 30 havingblood outlet 32 andbond socket 35. FIG. 3C depicts a side view of still another embodiment ofcap 30 havingblood outlet 32 andbond socket 35.Filter housing 10 is slideably received within the opening incap 30 when fully inserted,housing 10 rests againstannular ridge 36.Headspace 31 is defined by the gap betweenfilter 20 andcap 30. - FIG. 4A shows the details of
bond socket 35 communicating with the blood outlet designed for interference fit with appropriately sized tubing.Passage 41 has a dimension of approximately 0.185 inches in diameter.Surface 43 is approximately 0.248 inches in diameter.Annular member 42 has a height of approximately 0.35 inches.Surface 45 is approximately 0.252 inches in diameter. Thus,blood outlet 32 communicates with a quarter inch bond socket. Replacementfluid infusion port 33 communicates withbond socket 34 shown in details in FIG. 4B.Passage 41 has a dimension of approximately 0.098 inches in diameter.Surface 43 is approximately 0.142 inches in diameter.Annular member 42 has a height of approximately 0.31 inches.Surface 45 is approximately 0.147 inches in diameter. The foregoing ranges are set forth solely for the purpose of illustrating typical device dimensions. The actual dimensions of a device constructed according to the principles of the present invention may obviously vary outside of the listed ranges without departing from those basic principles. - FIG. 5 depicts
housing 10 inserted withincap 30.Headspace 31 communicates withoutlet 32, which in turn communicates withbond socket 35.Headspace 31 ranges from approximately 1.5 mm at the outer edge to approximately 3 mm in the center of the dome-like region. In use, the pressure inheadspace 31 can reach 40 PSI (2000 mmHg), resulting in 25 lbs force pushing the cap off. Thecap 30 may therefore need to be bonded, threaded, or snapped on, or attached by other suitable means, to withstand pressure. Solvent bonding and use of a threaded cap are two suitable means to accomplish attachment. It will again be understood that these device dimension are merely illustrative as stated above. FIG. 6 depicts a top view of another embodiment ofcap 30 havingribs 37. - Although the foregoing invention has, for the purposes of clarity and understanding, been described in some detail by way of illustration and example, it will be obvious that certain changes and modifications may be practiced which will still fall within the scope of the appended claims. For example, it will be understood that any feature of any device or method disclosed herein can be used with any of the other devices or methods, even though any given figure might depict only a particular combination.
Claims (57)
1. An extracorporeal filter, comprising:
a housing having an inlet for blood and an outlet for waste and ultrafiltrate;
a cap attached to the housing opposite the inlet, the cap having an outlet port for blood and an infusion port; and
a filter media received within the housing.
2. The filter of claim 1 , wherein the infusion port is radially adjacent the outlet port for blood.
3. The filter of claim 1 , wherein the cap is solvent bonded to the housing.
4. The filter of claim 1 , wherein the cap is removably attached to the housing.
5. The filter of claim 1 , wherein the port is adapted to receive replacement fluid.
6. The filter of claim 1 , wherein the housing has a second cap that carries the inlet.
7. The filter of claim 1 , further comprising a second port adapted to receive dilution fluid radially adjacent the inlet.
8. The filter of claim 1 , wherein a gap between the filter and the cap defines a headspace.
9. The filter of claim 1 , wherein the cap is molded of flexible PVC and is solvent bonded to the housing.
10. The filter of claim 1 , wherein the blood outlet communicates with a bond socket adapted to receive a flexible tubing.
11. The filter of claim 1 , wherein the housing is generally cylindrical.
12. The filter of claim 1 , wherein the replacement fluid port communicates with a bond socket adapted to receive a flexible tubing.
13. The filter of claim 1 , wherein the blood inlet communicates with a bond socket adapted to receive a flexible tubing.
14. The filter of claim 1 , wherein the waste outlet communicates with a bond socket adapted to receive a flexible tubing.
15. The filter of claim 1 , further comprising a second outlet for waste and ultrafiltrate.
16. The filter of claim 1 , further comprising a second inlet for blood.
17. A method for filtering blood, comprising the steps of:
providing a housing having a filter, an inlet for blood, an outlet for blood, a headspace between the filter and the outlet, and an infusion port communicating with the headspace;
passing blood through the inlet;
passing blood through the filter;
passing blood through the outlet; and
infusing dilution fluid into the infusion port to produce hemodilution at the outlet.
18. The method of claim 17 , further comprising the step of infusing dilution fluid into a port adjacent the inlet to produce hemodilution at the inlet.
19. The method of claim 17 , wherein the housing is cylindrical.
20. The method of claim 17 , wherein the dilution fluid swirls in a circular pattern in a gap between the filter and the outlet.
21. The method of claim 17 , wherein the housing has an outlet for waste and ultrafiltrate.
22. The method of claim 17 , wherein the blood outlet is mounted on a cap that is solvent bonded on the housing.
23. The method of claim 17 , wherein the step of passing blood through the filter produces hemoconcentration at the outlet.
24. The method of claim 17 , wherein the step of passing blood through the filter removes waste and ultrafiltrate.
25. The method of claim 17 , wherein the dilution fluid is a physiologic replacement fluid.
26. The method of claim 17 , wherein the dilution fluid is saline.
27. The method of claim 17 , wherein the dilution fluid is sterile filtered dialysate.
28. The method of claim 17 , wherein the dilution fluid is Ringer's lactate.
29. A method for filtering blood, comprising the steps of:
providing a housing having an inlet for blood, an outlet for blood, and an infusion port adjacent the outlet, the housing having a filter,;
passing blood through the inlet;
passing blood through the filter;
passing blood through the outlet; and
infusing dilution fluid into the infusion port adjacent the outlet to produce hemodilution at the outlet.
30. The method of claim 29 , further comprising the step of infusing dilution fluid into a port adjacent the inlet to produce hemodilution at the inlet.
31. The method of claim 29 , wherein the housing is cylindrical.
32. The method of claim 29 , wherein the dilution fluid swirls in a circular pattern in a gap between the filter and the outlet.
33. The method of claim 29 , wherein the housing has an outlet for waste and ultrafiltrate.
34. The method of claim 29 , wherein the blood outlet is mounted on a cap that is solvent bonded on the housing.
35. The method of claim 29 , wherein the step of passing blood through the filter produces hemoconcentration at the outlet.
36. The method of claim 29 , wherein the step of passing blood through the filter removes waste and ultrafiltrate.
37. The method of claim 29 , wherein the dilution fluid is a physiologic replacement fluid.
38. The method of claim 29 , wherein the dilution fluid is saline.
39. The method of claim 29 , wherein the dilution fluid is sterile filtered dialysate.
40. The method of claim 29 , wherein the dilution fluid is Ringer's lactate.
41. The method of claim 29 , wherein there is a headspace between the filter and the outlet.
42. The method of claim 41 , wherein the dilution port communicates with the headspace.
43. A blood-processing device, comprising:
a housing having an inlet for blood and an outlet for waste;
a fiber membrane received within the housing; and
a cap attached to the housing opposite the inlet, the cap having an outlet for blood, a headspace between the fiber membrane and the cap, and an infusion port communicating with the headspace.
44. The blood-processing device of claim 43 , further comprising an inlet for dialysate.
45. The blood-processing device of claim 43 , further comprising a second port adapted to receive dilution fluid radially adjacent the inlet.
46. A blood-processing device, comprising:
a housing having an outlet for blood and an outlet for waste;
a fiber membrane received within the housing; and
a cap attached to the housing opposite the outlet, the cap having an inlet for blood, a headspace between the fiber membrane and the cap, and an infusion port communicating with the headspace.
47. The blood-processing device of claim 46 , further comprising an inlet for dialysate.
48. The blood-processing device of claim 46 , further comprising a second port adapted to receive dilution fluid radially adjacent the outlet.
49. The blood-processing device of claim 46 , wherein the infusion port is radially adjacent the inlet for blood.
50. A method for processing blood, comprising the steps of:
providing a housing having a fiber membrane, an inlet for blood, an outlet for blood, a headspace between the fiber membrane and the outlet, and an infusion port communicating with the headspace;
passing blood through the inlet;
passing blood into contact with the fiber membrane;
passing blood through the outlet; and
infusing dilution fluid into the infusion port to produce hemodilution at the outlet.
51. The method of claim 50 , wherein the housing further comprises an inlet for dialysate.
52. The method of claim 50 , wherein the housing further comprises a second port adapted to receive dilution fluid radially adjacent the inlet.
53. The method of claim 50 , wherein the infusion port is radially adjacent the outlet for blood.
54. A method for processing blood, comprising the steps of:
providing a housing having a fiber membrane, an inlet for blood, an outlet for blood, a headspace between the fiber membrane and the inlet, and an infusion port communicating with the headspace;
passing blood through the inlet;
infusing dilution fluid into the infusion port to produce hemodilution at the inlet;
passing blood into contact with the fiber membrane; and
passing blood through the outlet.
55. The method of claim 54 , wherein the housing further comprises an inlet for dialysate.
56. The method of claim 54 , wherein the housing further comprises a second port adapted to receive dilution fluid radially adjacent the outlet.
57. The method of claim 54 , wherein the infusion port is radially adjacent the inlet for blood.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/904,709 US20030010718A1 (en) | 2001-07-12 | 2001-07-12 | Hemodilution cap and methods of use in blood-processing procedures |
US10/774,127 US20050000882A1 (en) | 2001-07-12 | 2004-02-06 | Hemodilution cap and methods of use in blood-processing procedures |
US12/015,420 US7776219B2 (en) | 2001-07-12 | 2008-01-16 | Methods, devices, and systems for hemodilution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/904,709 US20030010718A1 (en) | 2001-07-12 | 2001-07-12 | Hemodilution cap and methods of use in blood-processing procedures |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/774,127 Division US20050000882A1 (en) | 2001-07-12 | 2004-02-06 | Hemodilution cap and methods of use in blood-processing procedures |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030010718A1 true US20030010718A1 (en) | 2003-01-16 |
Family
ID=25419613
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/904,709 Abandoned US20030010718A1 (en) | 2001-07-12 | 2001-07-12 | Hemodilution cap and methods of use in blood-processing procedures |
US10/774,127 Abandoned US20050000882A1 (en) | 2001-07-12 | 2004-02-06 | Hemodilution cap and methods of use in blood-processing procedures |
US12/015,420 Expired - Fee Related US7776219B2 (en) | 2001-07-12 | 2008-01-16 | Methods, devices, and systems for hemodilution |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/774,127 Abandoned US20050000882A1 (en) | 2001-07-12 | 2004-02-06 | Hemodilution cap and methods of use in blood-processing procedures |
US12/015,420 Expired - Fee Related US7776219B2 (en) | 2001-07-12 | 2008-01-16 | Methods, devices, and systems for hemodilution |
Country Status (1)
Country | Link |
---|---|
US (3) | US20030010718A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040193171A1 (en) * | 2003-03-31 | 2004-09-30 | Depuy Acromed, Inc. | Remotely-activated vertebroplasty injection device |
US20040195165A1 (en) * | 2003-04-04 | 2004-10-07 | Chf Solutions, Inc. | Hollow fiber filter for extracorporeal blood circuit |
US20050131332A1 (en) * | 2003-11-05 | 2005-06-16 | Thomas Kelly | High convection home hemodialysis/hemofiltration and sorbent system |
EP1944077A1 (en) * | 2006-11-27 | 2008-07-16 | Bucher Vaslin | Device for preventing the formation of deposits at the entrance of tubular or capillary membranes of a tangential filtration module |
US20080177215A1 (en) * | 2001-07-12 | 2008-07-24 | Nxstage Medical Inc. | Methods, devices, and systems for hemodilution |
US20090012456A1 (en) * | 2007-07-05 | 2009-01-08 | Baxter International Inc. | Dialysis system having disposable cassette |
US20090107902A1 (en) * | 2007-10-24 | 2009-04-30 | Baxter International Inc. | Personal hemodialysis system |
US20090124963A1 (en) * | 2007-11-09 | 2009-05-14 | Baxter International Inc. | Balanced flow dialysis machine |
US20090229466A1 (en) * | 2004-10-28 | 2009-09-17 | Brugger James M | Blood treatment dialyzer/filter for permitting gas removal |
US20110046535A1 (en) * | 2008-04-15 | 2011-02-24 | Joensson Lennart | Blood treatment apparatus |
US8038639B2 (en) | 2004-11-04 | 2011-10-18 | Baxter International Inc. | Medical fluid system with flexible sheeting disposable unit |
EP2735358A1 (en) * | 2012-11-22 | 2014-05-28 | Gambro Lundia AB | Capillary dialyzers |
US9764074B1 (en) | 2002-07-19 | 2017-09-19 | Baxter International Inc. | Systems and methods for performing dialysis |
WO2017171064A1 (en) * | 2016-03-31 | 2017-10-05 | 旭化成メディカル株式会社 | Blood purification system and method for priming of same |
JP2017185232A (en) * | 2016-03-31 | 2017-10-12 | 旭化成メディカル株式会社 | Blood purifier |
US10232103B1 (en) | 2001-11-13 | 2019-03-19 | Baxter International Inc. | System, method, and composition for removing uremic toxins in dialysis processes |
US10596236B2 (en) | 2016-03-10 | 2020-03-24 | Arthrex, Inc. | Systems and methods for preparing a thrombin serum |
US10960026B2 (en) | 2016-03-10 | 2021-03-30 | Arthrex, Inc. | Systems and methods for preparing protein enhanced serums |
JP7085800B2 (en) | 2016-03-31 | 2022-06-17 | 旭化成メディカル株式会社 | Blood purifier, blood purification kit, and blood purification system |
US11931492B2 (en) | 2021-06-30 | 2024-03-19 | Baxter International Inc. | Balanced flow dialysis machine |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8753515B2 (en) | 2009-12-05 | 2014-06-17 | Home Dialysis Plus, Ltd. | Dialysis system with ultrafiltration control |
US8501009B2 (en) | 2010-06-07 | 2013-08-06 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Fluid purification system |
US20120157905A1 (en) * | 2010-12-15 | 2012-06-21 | Biovec Transfusion, Llc | Methods for treating carbon monoxide poisoning by tangential flow filtration of blood |
WO2013052680A2 (en) | 2011-10-07 | 2013-04-11 | Home Dialysis Plus, Ltd. | Heat exchange fluid purification for dialysis system |
EP3131663A2 (en) | 2014-03-29 | 2017-02-22 | Princeton Trade and Technology Inc. | Blood processing cartridges and systems, and methods for extracorporeal blood therapies |
ES2864727T3 (en) | 2014-04-29 | 2021-10-14 | Outset Medical Inc | Dialysis system and methods |
US10426884B2 (en) | 2015-06-26 | 2019-10-01 | Novaflux Inc. | Cartridges and systems for outside-in flow in membrane-based therapies |
EP3352888B8 (en) | 2015-09-24 | 2022-01-12 | Princeton Trade and Technology Inc. | Cartridges for hollow fibre membrane-based therapies |
RU167888U1 (en) * | 2015-10-13 | 2017-01-11 | федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский национальный исследовательский технологический университет" (ФГБОУ ВО "КНИТУ") | Dialyzer |
EP3500317B1 (en) | 2016-08-19 | 2022-02-23 | Outset Medical, Inc. | Peritoneal dialysis system and methods |
DE102018100568A1 (en) | 2018-01-11 | 2019-07-11 | B. Braun Avitum Ag | Blood treatment machine with a hollow fiber filter module for horizontal arrangement and a hollow fiber filter module and its use |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4047563A (en) * | 1976-01-27 | 1977-09-13 | Japan Medical Supply Co., Ltd. | Heat exchanger for artificial heart and lung devices |
US4201673A (en) * | 1977-07-04 | 1980-05-06 | Terumo Corporation | Apparatus for dialysis of solution |
ZA8680B (en) * | 1985-01-08 | 1987-08-26 | Mcneilab Inc | Mass transfer device having a microporous,spirally wound hollow fiber membrane |
US4828543A (en) * | 1986-04-03 | 1989-05-09 | Weiss Paul I | Extracorporeal circulation apparatus |
DE3709432A1 (en) * | 1987-03-21 | 1988-10-06 | Fresenius Ag | CAPILLARY FILTER ARRANGEMENT FOR THE STERILIZATION OF LIQUID MEDIA |
JPH0614965B2 (en) * | 1989-01-10 | 1994-03-02 | テルモ株式会社 | Oxygenator |
US5051113A (en) | 1990-06-13 | 1991-09-24 | Du Pont Canada Inc. | Air-intake system for mobile engines |
SE502103C2 (en) * | 1991-08-01 | 1995-08-14 | Gambro Dialysatoren | Filter unit for transfer of pulp and / or heat containing cavity fibers |
US5264171A (en) * | 1991-12-31 | 1993-11-23 | Hoechst Celanese Corporation | Method of making spiral-wound hollow fiber membrane fabric cartridges and modules having flow-directing baffles |
US5480552A (en) * | 1992-01-10 | 1996-01-02 | Baxter International Inc. | Method for concentrating a solute with an oscillating filtration device |
DE19607162C2 (en) * | 1996-02-26 | 1998-01-15 | Fresenius Ag | Use of a two module dialyzer to perform a method of filtering and immediately using substituate fluid in a hemodial filtration device |
US5762869A (en) * | 1996-07-24 | 1998-06-09 | Gish Biomedical, Inc. | Blood oxygenator |
US5820767A (en) * | 1996-07-29 | 1998-10-13 | Pall Corporation | Method for quantitation of microorganism contamination of liquids |
US5916647A (en) * | 1996-09-25 | 1999-06-29 | Celgard Llc | Pressure vessel: overmolding a polyolefin onto a polyolefin |
ES2208806T3 (en) * | 1996-11-21 | 2004-06-16 | Fresenius Medical Care Deutschland Gmbh | HIBLE FIBER MEMBRANE SEPARATOR DEVICE. |
US6582385B2 (en) | 1998-02-19 | 2003-06-24 | Nstage Medical, Inc. | Hemofiltration system including ultrafiltrate purification and re-infusion system |
US6303036B1 (en) | 1998-07-31 | 2001-10-16 | Nephros, Inc. | Method and apparatus for efficient hemodiafiltration |
US6050278A (en) * | 1998-09-24 | 2000-04-18 | Minntech Corporation | Dialyzer precleaning system |
SE523122C2 (en) | 1999-03-05 | 2004-03-30 | Gambro Dialysatoren | Filters with hollow fiber membrane |
US6406631B1 (en) | 1999-07-30 | 2002-06-18 | Nephros, Inc. | Two stage diafiltration method and apparatus |
US6387324B1 (en) * | 1999-09-30 | 2002-05-14 | Therox, Inc. | Apparatus and method for blood oxygenation |
JP2003511103A (en) | 1999-10-06 | 2003-03-25 | メムブラーナ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Membrane module for hemodiafiltration with integrated pre-dilution or post-dilution of blood |
US6776912B2 (en) * | 1999-12-23 | 2004-08-17 | Membrana Gmbh | Hemodiafiltration system and method |
US6315895B1 (en) | 1999-12-30 | 2001-11-13 | Nephros, Inc. | Dual-stage hemodiafiltration cartridge |
IT1320024B1 (en) | 2000-04-07 | 2003-11-12 | Gambro Dasco Spa | METHOD FOR ADJUSTING THE INFUSION IN A DIALYSIS MACHINE AND DIALYSIS MACHINE FOR THE APPLICATION OF THE MENTIONED METHOD. |
ES2344140T3 (en) | 2000-10-30 | 2010-08-19 | Nephros Inc | TWO STAGE FILTRATION CARTRIDGE. |
MXPA03005225A (en) * | 2000-12-11 | 2004-12-02 | Nephros Inc | Hemodiafiltration / hemofiltration cartridges. |
US20030010718A1 (en) * | 2001-07-12 | 2003-01-16 | Nxstage Medical, Inc. | Hemodilution cap and methods of use in blood-processing procedures |
US6702561B2 (en) * | 2001-07-12 | 2004-03-09 | Nxstage Medical, Inc. | Devices for potting a filter for blood processing |
US7125396B2 (en) * | 2002-12-30 | 2006-10-24 | Cardinal Health 303, Inc. | Safety catheter system and method |
US7297270B2 (en) | 2003-04-04 | 2007-11-20 | Chf Solutions, Inc. | Hollow fiber filter for extracorporeal blood circuit |
US7744553B2 (en) | 2003-12-16 | 2010-06-29 | Baxter International Inc. | Medical fluid therapy flow control systems and methods |
US7534349B2 (en) | 2005-09-02 | 2009-05-19 | Nephros, Inc. | Dual stage ultrafilter devices in the form of portable filter devices, shower devices, and hydration packs |
US8281937B2 (en) | 2007-02-16 | 2012-10-09 | Nephros, Inc. | Compact fluid purification device with manual pumping mechanism |
-
2001
- 2001-07-12 US US09/904,709 patent/US20030010718A1/en not_active Abandoned
-
2004
- 2004-02-06 US US10/774,127 patent/US20050000882A1/en not_active Abandoned
-
2008
- 2008-01-16 US US12/015,420 patent/US7776219B2/en not_active Expired - Fee Related
Cited By (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080177215A1 (en) * | 2001-07-12 | 2008-07-24 | Nxstage Medical Inc. | Methods, devices, and systems for hemodilution |
US7776219B2 (en) | 2001-07-12 | 2010-08-17 | Nxstage Medical, Inc. | Methods, devices, and systems for hemodilution |
US10232103B1 (en) | 2001-11-13 | 2019-03-19 | Baxter International Inc. | System, method, and composition for removing uremic toxins in dialysis processes |
US10980931B2 (en) | 2001-11-13 | 2021-04-20 | Baxter International Inc. | System, method, and composition for removing uremic toxins in dialysis processes |
US9764074B1 (en) | 2002-07-19 | 2017-09-19 | Baxter International Inc. | Systems and methods for performing dialysis |
US20040193171A1 (en) * | 2003-03-31 | 2004-09-30 | Depuy Acromed, Inc. | Remotely-activated vertebroplasty injection device |
US20040195165A1 (en) * | 2003-04-04 | 2004-10-07 | Chf Solutions, Inc. | Hollow fiber filter for extracorporeal blood circuit |
US7297270B2 (en) * | 2003-04-04 | 2007-11-20 | Chf Solutions, Inc. | Hollow fiber filter for extracorporeal blood circuit |
US20080060990A1 (en) * | 2003-04-04 | 2008-03-13 | Chf Solutions Inc. | Hollow fiber filter for extracorporeal blood circuit |
US7410582B2 (en) | 2003-04-04 | 2008-08-12 | Chf Solutions Inc. | Hollow fiber filter for extracorporeal blood circuit |
US9872950B2 (en) | 2003-11-05 | 2018-01-23 | Baxter International Inc. | Renal therapy system having pump reversing fluid control |
US9480784B2 (en) | 2003-11-05 | 2016-11-01 | Baxter International Inc. | Dialysis system with balance chamber prime and rinseback |
US10155080B2 (en) | 2003-11-05 | 2018-12-18 | Baxter International Inc. | Renal therapy system with cassette-based blood and dialysate pumping |
US10245370B2 (en) | 2003-11-05 | 2019-04-02 | Baxter International Inc. | Renal failure therapy machines and methods including convective and diffusive clearance |
US20110004351A1 (en) * | 2003-11-05 | 2011-01-06 | Baxter International Inc. | Dialysis system including downloaded prescription entry |
US20110000832A1 (en) * | 2003-11-05 | 2011-01-06 | Baxter International Inc. | Dialysis system with enhanced features |
US20110009798A1 (en) * | 2003-11-05 | 2011-01-13 | Baxter International Inc. | Renal therapy system having pump reversing fluid control |
US20110005992A1 (en) * | 2003-11-05 | 2011-01-13 | Baxter International Inc. | Dialysis system with balance chamber prime and rinseback |
US9889243B2 (en) | 2003-11-05 | 2018-02-13 | Baxter International Inc. | Dialysis system including automatic priming |
US9884144B2 (en) | 2003-11-05 | 2018-02-06 | Baxter International Inc. | Hemodialysis system with cassette-based blood and dialysate pumping |
US10293096B2 (en) | 2003-11-05 | 2019-05-21 | Baxter International Inc. | Dialysis system including cassette with pumping tubes |
US8029454B2 (en) | 2003-11-05 | 2011-10-04 | Baxter International Inc. | High convection home hemodialysis/hemofiltration and sorbent system |
US9072831B2 (en) | 2003-11-05 | 2015-07-07 | Baxter International Inc. | Medical fluid pump valve integrity test methods and systems |
US20050131332A1 (en) * | 2003-11-05 | 2005-06-16 | Thomas Kelly | High convection home hemodialysis/hemofiltration and sorbent system |
US9642961B2 (en) | 2003-11-05 | 2017-05-09 | Baxter International Inc. | Renal failure therapy machines and methods including convective and diffusive clearance |
US9572919B2 (en) | 2003-11-05 | 2017-02-21 | Baxter International Inc. | Dialysis system with cassette based balance chambers and volumetric pumps |
US9550020B2 (en) | 2003-11-05 | 2017-01-24 | Baxter International Inc. | Dialysis system with a varying rate ultrafiltration profile |
US10183109B2 (en) | 2003-11-05 | 2019-01-22 | Baxter International Inc. | Hemodialysis system including a disposable cassette |
US9421313B2 (en) | 2003-11-05 | 2016-08-23 | Baxter International Inc. | Hemodialysis system with horizontal cassette roller pumps |
US9387286B2 (en) | 2003-11-05 | 2016-07-12 | Baxter International Inc. | Dialysis system including peristaltic tubing pumping cassette |
US9302039B2 (en) | 2003-11-05 | 2016-04-05 | Baxter International Inc. | Hemodialysis system including a disposable cassette |
US9216246B2 (en) | 2003-11-05 | 2015-12-22 | Baxter International Inc. | Renal failure therapy machines and methods including conductive and convective clearance |
US9168333B2 (en) | 2003-11-05 | 2015-10-27 | Baxter International Inc. | Dialysis system including disposable cassette |
US8858488B2 (en) | 2003-11-05 | 2014-10-14 | Baxter International Inc. | Dialysis system including blood and dialysate cassette |
US8882692B2 (en) | 2003-11-05 | 2014-11-11 | Baxter International Inc. | Hemodialysis system with multiple cassette interference |
US8894600B2 (en) | 2003-11-05 | 2014-11-25 | Baxter International Inc. | Hemodialysis system including on-line dialysate generation |
US9155825B2 (en) | 2003-11-05 | 2015-10-13 | Baxter International Inc. | Hemodialysis system using sorbent and reservoir |
US8926540B2 (en) | 2003-11-05 | 2015-01-06 | Baxter Healthcare Inc. | Hemodialysis system with separate dialysate cassette |
US9144641B2 (en) | 2003-11-05 | 2015-09-29 | Baxter International Inc. | Dialysis system with balance chamber prime and rinseback |
US9072830B2 (en) | 2003-11-05 | 2015-07-07 | Baxter International Inc. | Systems and methods for priming sorbent-based hemodialysis |
US9072843B2 (en) | 2003-11-05 | 2015-07-07 | Baxter International Inc. | Renal therapy system having pump reversing fluid control |
US9005152B2 (en) | 2003-11-05 | 2015-04-14 | Baxter International Inc. | Dialysis system with cassette based balance chambers and volumetric pumps |
US9028436B2 (en) | 2003-11-05 | 2015-05-12 | Baxter International Inc. | Hemodialysis system with cassette-based blood and dialyste pumping |
US9039648B2 (en) | 2003-11-05 | 2015-05-26 | Baxter International Inc. | Dialysis system with enhanced features |
US9050411B2 (en) | 2003-11-05 | 2015-06-09 | Baxter International Inc. | Dialysis system including downloaded prescription entry |
US20110126714A1 (en) * | 2004-10-28 | 2011-06-02 | Nxstage Medical, Inc. | Blood treatment dialyzer/filter for permitting gas removal |
US20090229466A1 (en) * | 2004-10-28 | 2009-09-17 | Brugger James M | Blood treatment dialyzer/filter for permitting gas removal |
US20100096311A1 (en) * | 2004-10-28 | 2010-04-22 | Nxstage Medical, Inc | Blood treatment dialyzer/filter design to trap entrained air in a fluid circuit |
US7901579B2 (en) | 2004-10-28 | 2011-03-08 | Nxstage Medical, Inc. | Blood treatment dialyzer/filter for permitting gas removal |
US8038639B2 (en) | 2004-11-04 | 2011-10-18 | Baxter International Inc. | Medical fluid system with flexible sheeting disposable unit |
EP2508248A1 (en) * | 2006-11-27 | 2012-10-10 | Bucher Vaslin (Société Anonyme) | Device for preventing the formation of deposits at the entrance of tubular or capillary membranes of a tangential filtration module |
EP1944077A1 (en) * | 2006-11-27 | 2008-07-16 | Bucher Vaslin | Device for preventing the formation of deposits at the entrance of tubular or capillary membranes of a tangential filtration module |
US20090012456A1 (en) * | 2007-07-05 | 2009-01-08 | Baxter International Inc. | Dialysis system having disposable cassette |
US8920362B2 (en) | 2007-07-05 | 2014-12-30 | Baxter International Inc. | Dialysis system having disposable cassette |
US8057423B2 (en) | 2007-07-05 | 2011-11-15 | Baxter International Inc. | Dialysis system having disposable cassette |
US8337449B2 (en) | 2007-07-05 | 2012-12-25 | Baxter International Inc. | Dialysis system having disposable cassette |
US10695479B2 (en) | 2007-10-24 | 2020-06-30 | Baxter International Inc. | Renal therapy machine and method including a priming sequence |
US8932469B2 (en) | 2007-10-24 | 2015-01-13 | Baxter International Inc. | Personal hemodialysis system including priming sequence and methods of same |
US8329030B2 (en) | 2007-10-24 | 2012-12-11 | Baxter International Inc. | Hemodialysis system with cassette and pinch clamp |
US8114276B2 (en) | 2007-10-24 | 2012-02-14 | Baxter International Inc. | Personal hemodialysis system |
US20090107902A1 (en) * | 2007-10-24 | 2009-04-30 | Baxter International Inc. | Personal hemodialysis system |
US11291752B2 (en) | 2007-10-24 | 2022-04-05 | Baxter International Inc. | Hemodialysis system including a disposable set and a dialysis instrument |
US9925320B2 (en) | 2007-10-24 | 2018-03-27 | Baxter International Inc. | Renal therapy machine and system including a priming sequence |
US9855377B2 (en) | 2007-10-24 | 2018-01-02 | Baxter International Inc. | Dialysis system including heparin injection |
US8323492B2 (en) | 2007-10-24 | 2012-12-04 | Baxter International Inc. | Hemodialysis system having clamping mechanism for peristaltic pumping |
US8834719B2 (en) | 2007-10-24 | 2014-09-16 | Baxter International Inc. | Personal hemodialysis system |
US8992463B2 (en) | 2007-11-09 | 2015-03-31 | Baxter International Inc. | Balanced flow dialysis machine |
US11052180B2 (en) | 2007-11-09 | 2021-07-06 | Baxter International Inc. | Balanced flow dialysis machine |
US9415150B2 (en) | 2007-11-09 | 2016-08-16 | Baxter Healthcare S.A. | Balanced flow dialysis machine |
US20090124963A1 (en) * | 2007-11-09 | 2009-05-14 | Baxter International Inc. | Balanced flow dialysis machine |
US8652082B2 (en) * | 2008-04-15 | 2014-02-18 | Gambro Lundia Ab | Blood treatment apparatus |
US20110046535A1 (en) * | 2008-04-15 | 2011-02-24 | Joensson Lennart | Blood treatment apparatus |
EP2735358A1 (en) * | 2012-11-22 | 2014-05-28 | Gambro Lundia AB | Capillary dialyzers |
WO2014079991A1 (en) * | 2012-11-22 | 2014-05-30 | Gambro Lundia Ab | Capillary dialyzers |
CN104349833A (en) * | 2012-11-22 | 2015-02-11 | 甘布罗伦迪亚股份公司 | Capillary dialyzers |
US10960026B2 (en) | 2016-03-10 | 2021-03-30 | Arthrex, Inc. | Systems and methods for preparing protein enhanced serums |
US10596236B2 (en) | 2016-03-10 | 2020-03-24 | Arthrex, Inc. | Systems and methods for preparing a thrombin serum |
US11045526B2 (en) | 2016-03-10 | 2021-06-29 | Arthrex, Inc. | Systems and methods for preparing a thrombin serum |
US11617784B2 (en) | 2016-03-10 | 2023-04-04 | Arthrex, Inc. | Systems and methods for preparing a thrombin serum |
CN109069723A (en) * | 2016-03-31 | 2018-12-21 | 旭化成医疗株式会社 | Blood purification system and its starting charging method |
JPWO2017171064A1 (en) * | 2016-03-31 | 2018-11-22 | 旭化成メディカル株式会社 | Blood purification system and priming method thereof |
JP2017185232A (en) * | 2016-03-31 | 2017-10-12 | 旭化成メディカル株式会社 | Blood purifier |
CN113304341A (en) * | 2016-03-31 | 2021-08-27 | 旭化成医疗株式会社 | Blood purification system and priming method thereof |
WO2017171064A1 (en) * | 2016-03-31 | 2017-10-05 | 旭化成メディカル株式会社 | Blood purification system and method for priming of same |
JP7085800B2 (en) | 2016-03-31 | 2022-06-17 | 旭化成メディカル株式会社 | Blood purifier, blood purification kit, and blood purification system |
US11931492B2 (en) | 2021-06-30 | 2024-03-19 | Baxter International Inc. | Balanced flow dialysis machine |
Also Published As
Publication number | Publication date |
---|---|
US20080177215A1 (en) | 2008-07-24 |
US7776219B2 (en) | 2010-08-17 |
US20050000882A1 (en) | 2005-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7776219B2 (en) | Methods, devices, and systems for hemodilution | |
US5417650A (en) | Apparatus for separating plasma and other wastes from blood | |
CA1270448A (en) | Unitary venous return reservoir with cardiotomy filter | |
KR101099962B1 (en) | Fluid distribution module and extracorporeal blood circuit including such a module | |
EP1323462B1 (en) | Filtering device with associated sealing design and method | |
JP4861649B2 (en) | Blood component collection circuit and blood component collection device | |
KR910002208B1 (en) | Blood component separator | |
CA2544612C (en) | Degassing device and end-cap assembly for a filter including such a degassing device | |
US4935002A (en) | Apparatus and method for the autotransfusion of blood | |
EP0333119B1 (en) | Liquid filtering device | |
US4737139A (en) | Unitary venous return reservoir with cardiotomy filter | |
EP0745397B1 (en) | Blood filter and extracorporeal circuit | |
AU6182298A (en) | In-line gravity driven liquid filtration device useable to filter blood or blood products | |
JPS6314992B2 (en) | ||
US20090236027A1 (en) | Blood Treatment Filter and Method of Manufacturing | |
JP4027686B2 (en) | Dialysis machine | |
EP3789060B1 (en) | Air trap chamber and extracorporeal circulation circuit | |
JPS64937Y2 (en) | ||
EP4065189A1 (en) | Pressure relief mechanism for sorbent canisters | |
SU1090415A1 (en) | Filter for blood transfusion | |
JPH08141076A (en) | Blood purifying device and blood purifying means and blood purifying method using this device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NXSTAGE MEDICAL, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BURBANK, JEFFREY H.;STILLIG, MARTIN;BRUGGER, JAMES M.;REEL/FRAME:011997/0273 Effective date: 20010605 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |